A Comprehensive Review on Copemyl®-Reference-Cited by-同舟云学术

A Comprehensive Review on Copemyl®

Published:2017-07-31 Issue:2 Volume:6 Page:161-173
ISSN:2193-8253
Container-title:Neurology and Therapy
language:en
Short-container-title:Neurol Ther

Author:

Annovazzi Pietro,Bertolotto Antonio,Brescia Morra Vincenzo,Gasperini Claudio,Montanari Enrico,Navarra Pierluigi,Patti Francesco,Sormani Maria Pia,Ghezzi Angelo

Funder

Mylan BGP products srl

Publisher

Springer Science and Business Media LLC

Subject

Neurology (clinical),Neurology

Link

http://link.springer.com/content/pdf/10.1007/s40120-017-0079-3.pdf

Reference50 articles.

1. Johnson KP. Glatiramer acetate and the glatiramoid class of immunomodulator drugs in multiple sclerosis: an update. Expert Opin Drug Metab Toxicol. 2010;6(5):643–60.

2. Comi G, Amato MP, Bertolotto A, et al. The heritage of glatiramer acetate and its use in multiple sclerosis. Mult Scler Demyelin Disord. 2016;1:6.

3. Arnon R. The development of Cop 1 (Copaxone), an innovative drug for the treatment of multiple sclerosis: personal reflections. Immunol Lett. 1996;50(1–2):1–15.

4. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M. Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide. Eur J Immunol. 1971;1(4):242–8.

5. Aharoni R, Teitelbaum D, Sela M, Arnon R. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol. 1998;91(1–2):135–46.

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adult and pediatric relapsing multiple sclerosis phase II and phase III trial design and their primary end points: A systematic review;Clinical and Translational Science;2024-05

2. An update on the safety of treating relapsing-remitting multiple sclerosis;Expert Opinion on Drug Safety;2019-08-30

3. Glatiramer acetate: A complex drug beyond biologics;European Journal of Pharmaceutical Sciences;2019-05

4. Authors’ Response to the Letter to the Editor Regarding: A Comprehensive Review on Copemyl®;Neurology and Therapy;2018-11-10

5. Letter to the Editor Regarding: A Comprehensive Review on Copemyl®;Neurology and Therapy;2018-11-10